Follicular lymphoma: Have we made any progress?

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Horning, S J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fludarabine; Follicular lymphoma; Interferon; Rituximab; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; FLUDARABINE; INTERFERON;

CANCER RECURRENCE; CANCER REGRESSION; CONFERENCE PAPER; DRUG RESEARCH; FOLLICULAR LYMPHOMA; GENE THERAPY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0034002981     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S23     Document Type: Conference Paper

References (34)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982: 49 (10): 1112-35.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20 (5, Suppl 5): 75-88.
3. Hoppe RT, Kushlan P, Kaplan HS et al. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: A preliminary report of a randomized trial comparing single-agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981: 58 (3): 592-8.
4. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993: 11 (4): 644-51.
5. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311 (23): 1471-5.
6. Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: Watchful waiting vs. aggressive combined modality treatment. Semin Hematol 1988; 11-6.
7. Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon-α: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997: 15 (3): 1110-7.
8. NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology 1997: 11 (11A): 281-346.
9. Solal-Céligny P, Lepage E. Brousse N et al. Doxorubiein-containing regimen with or without interferon-α-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16 (7): 2332-8.
10. Smalley RV, Andersen JW, Hawkins MJ et al. Interferon-α combined with cytoloxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327 (19): 1336-41.
11. Unterhalt M, Hermann R. Koch P. Trumper L. Prognostic determinants for long-term outcome of low-grade follicular lymphomas after cytoreductive chemotherapy and interferon-α maintenance. Results of the German Low-Grade Lymphoma Study Group. Blood 1997; 90: 392 (Abstr 1743).
12. Dana BW, Unger J, Fisher RI. A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to ProMACE-MOPP (SWOG 8809). Proc Am Soc Clin Oncol 1998; 17: 3a (Abstr 10).
13. Rohatiner A, Gregory W, Peterson B, Smalley R. A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma. Proc Am Soc Clin Oncol 1998; 17: 4a (Abstr 11).
14. Solal-Céligny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996: 14 (2): 514-9.
15. McLaughlin P. Hagemeister FB, Romaguera JE et al. Fludarahine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14 (4): 1262-8.
16. Hochster H, Oken M, Winter J et al. Prolonged time to progression in patients with low-grade lymphoma treated with cyclophosphamide and fludarabine (ECOG 1491). Proc Am Soc Clin Oncol 1998; 17: 17a.
17. Hagenbeek A, Eghbali H, Monfardini S, Resegolti E. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients, Blood 1998; 10 (Suppl 1): 1294 (Abstr).
18. Velasques W, Lew D. Miller T, Fisher R. SWOG 95-01: A phase 11 trial of a combination of fludarabine and mitoxantrone in untreated advanced low-grade lymphoma: An effective well-tolerated therapy. Proc Am Soc Clin Oncol 1998; 18: 9a (Abstr 27).
19. Freedman A, Gribben J, Neuberg D, Mauch P. Long-term prolongation of disease-free and overall survival following autologous bone marrow transplantation in patients with advanced relapsed follicular lymphoma. Proc Am Soc Clin Oncol 1997; 16: 89a (Abstr 314).
20. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12(6): 1177-84.
21. Bociek G, Bierman P. Lynch J, Morris M. High-dose therapy with autologous hematopoietic stem-cell transplantation for follicular non-Hodgkin's lymphoma: Long-term results. Proc Am Soc Clin Oncol 1999: 19: 3a (Abstr 8).
22. Freedman AS, Gribben JG. Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoina during first remission. Blood 1996; 88 (7): 2780-6.
23. Horning SJ, Negrin RS, Hoppe RT, Chao NJ. High-dose therapy and autografting for follicular low-grade lymphoma in first remission: The Stanford experience. Blood 1997; 90 (Suppl 1): 594a (Abstr 2641).
24. Gribhen JG, Neuherg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the BCL-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81 (12): 3449-57.
25. Lopez-Guillermo A. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma. Update of the MDACC series. Proc VII International Conference on Malignant Lymphoma, Lugano, Switzerland 1999.
26. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Ritimmab ehimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 (8): 2825-33.
27. Czuczman MS. Grillo-Lopez A, White CA, Saleh M. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
28. Kaminski MS. Zelenetz A, Press O, Saleh M. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low-grade non-Hodgkin's lymphoma. Blood 1998; 92 (Suppl 1) (Abstr 1296).
29. Press OW. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am 1998; 4 (10, Suppl 2): S19-26.
30. Wiseman GA, White CA, Stabin M, Gordon L. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: Up to 850-fold greater radiation dose to tumor than to normal organs. Proc Am Soc Clin Oncol 1999; 18: 4a (Abstr 13).
31. Cheson BD, Horning SJ, Coiffier b, Shipp MA. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-53.
32. Hsu KJ, Caspar CB, Czerwinski D et al. Tumor-specitic idiotype vaccines in the treatment of patients with B-cell lymphoma long-term results of a clinical trial. Blood 1997; 89 (9): 3129-35.
33. Cotter FE. Antisense therapy for B-cell lymphomas. Cancer Surveys 1997; 30 (1): 311-25.
34. van Besien K,Thall P, Korbling M et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: Experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997; 3 (3): 150-6.